ADC Therapeutics SA

Welcome to the ADC Therapeutics fourth quarter and year end 2021 financial results conference call. My name is Josh and I will be your operator for today's call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session. During the question and answer session, if you have a question, please press star, then one on your touchstone telephone. I will now turn the call over to Amanda Hamilton, investor relations manager. Amanda, you may begin.

Thank you, Operator. This morning, we issued a press release announcing our fourth quarter and year-end 2021 financial results and business updates. This release is available on the ADCT website at ir.adctherapeutics.com under the Press Releases section. On today's call, Chris Martin, Chief Executive Officer, Jennifer Herron, Chief Commercial Officer, Joe Camardo, Chief Medical Officer, and Jen Creel, Chief Financial Officer, We'll discuss recent business highlights and review our fourth quarter and full year 2021 financial results before opening the call for questions. As a reminder, this conference call may contain forward-looking statements. Such statements are subject to risks and uncertainties. For additional information concerning forward-looking statements and factors that could cause actual results to differ materially from those expressed or implied in these statements, we refer you to the section titled Cautionary Statements Regarding Forward-Looking Statements in Exhibit 99.3 of our report on Form 6-K filed with the U.S. Securities and Exchange Commission earlier today. Such statements speak only as of the date of this conference call, and we expressly disclaim any obligation or undertaking to update these forward-looking statements unless required to do so by applicable law. Today's presentation also includes non-IFRS financial measures. These non-IFRS measures have limitations as financial measures and should be considered in addition to and not in isolation or as a substitute for the information prepared in accordance with IFRS. You should refer to the information contained in the company's fourth quarter earnings release for definitional information and reconciliations of historical non-IFRS measures to the comparable IFRS financial measures. It is now my pleasure to pass the call over to our CEO, Chris Martin. Chris?

Thanks, Amanda, and thank you, everyone, for joining us today. I'm very pleased to share our fourth quarter and full year results as we executed on our key objectives and closed out a pivotal year for ADC Therapeutics. I'm also looking forward to sharing our 2022 milestones with you. The Zinnota launch remains a top priority, and we're very encouraged by what we have been able to accomplish so far. In addition, we have advanced our clinical development portfolio and research pipeline, and we are entering the year with a healthy cash balance. Starting with the launch, we delivered 17 million in net sales during the fourth quarter and approximately 34 million for the eight months of sales in 2021. The differentiated product profile of Zinlanta continues to serve an unmet need in the third-line plus DLBCL market. and is resonating with physicians both at major academic centers and in the community as they consider treatment options for their patients. The positive launch dynamics are also a testament to our experienced commercial team, which has been able to navigate the challenges of the evolving COVID landscape. Jennifer Herron, our Chief Commercial Officer, will share more details on our Q4 and 2021 performance a little later in this call. Next, we remain committed to expanding worldwide access for any relapsed refractory DLBCL patient who may benefit from Zynlanta, and we are working to expand our geographic footprint. During the fourth quarter, the EMA validated our marketing authorization application, and in January, we announced an exclusive license with Mitsubishi Tanabe for the development and commercialization of Zynlanta in Japan. The Overland ADCT BioPharm joint venture continues to enroll patients in the pivotal Phase II bridging study in China, which is intended to serve as the basis for regulatory filing. The joint venture is making rapid progress towards bringing Zinlanta to patients in China. We will continue to focus on moving Zinlanta into first and second line DLBCL therapy with promising combinations that may offer a path to registration. including our ongoing confirmatory phase three study of Zynlonta in combination with rituximab, as well as our frontline study in the same combination in unfit or frail patients. We have refined our Zynlonta development strategy, prioritizing areas where we can bring the most differentiated benefit to patients and healthcare providers, which would also result in increased value for all stakeholders. Joe Comardo, our chief medical officer, will elaborate on this in a moment. In addition to Zinlanta, we continue to advance the programs in our robust clinical development and research pipeline, which will ensure long-term growth and value creation for the company. For CAMI, we have completed the 12-month follow-up of the pivotal Phase II trial in relapsed refractory Hodgkin's lymphoma, and we have submitted the data to an upcoming meeting. As we highlighted on our Solid Tumor Pipeline webcast in February, we see significant potential for our pipeline of solid tumor programs, which includes three clinical programs in CAMI, ADCT901 targeting CAG1, and ADCT601 targeting Axel. We also have two preclinical programs with ADCT701 targeting DLK1 and ADCT212 targeting PSMA. This exciting pipeline demonstrates the impact of our expanding ADC platform and the productivity of our experienced team of industry experts. Jo will tell you more about our solid tumor program shortly. I would now like to turn the call over to Jennifer to report on the launch and provide insights on our progress in establishing Zynlanta as a third line plus standard of care in DLBCL. Jennifer.